2 results
Approved WMOPending
To compare invasive disease-free survival (iDFS) for ribociclib + ET versus placebo + ET in patients with HR-positive, HER2-negative, EBCwith high risk of recurrence.
Approved WMORecruiting
To determine the effectiveness of more intensive BP lowering provided by a *Triple Pill* strategy on top of standard of care, on the time to first occurrence of recurrent stroke after ICH.